AR033426A1 - Uso de compuestos carbamatos en la prevencion o el tratamiento de trastornos de movimiento - Google Patents

Uso de compuestos carbamatos en la prevencion o el tratamiento de trastornos de movimiento

Info

Publication number
AR033426A1
AR033426A1 ARP020100698A ARP020100698A AR033426A1 AR 033426 A1 AR033426 A1 AR 033426A1 AR P020100698 A ARP020100698 A AR P020100698A AR P020100698 A ARP020100698 A AR P020100698A AR 033426 A1 AR033426 A1 AR 033426A1
Authority
AR
Argentina
Prior art keywords
group
movement disorders
alkyl
prevention
treatment
Prior art date
Application number
ARP020100698A
Other languages
English (en)
Original Assignee
Ortho Mcneil Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Mcneil Pharm Inc filed Critical Ortho Mcneil Pharm Inc
Publication of AR033426A1 publication Critical patent/AR033426A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/325Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Un método para prevenir o tratar trastornos del movimiento que comprende la administracion a un sujeto que así lo requiera, de una cantidad terapéuticamente efectiva de un compuesto seleccionado del grupo consistente de la formula (1) y de la formula (2), en las cuales: el grupo fenilo está sustituido en X con 1-5 átomos de halogenos seleccionados del grupo que consiste de fluor, cloro, bromo y yodo; y R1, R2, R3, R4, R5 y R6 son seleccionados independientemente del grupo que consiste de hidrogeno y alquilo C1-4; en el cual el alquilo C1-4 está opcionalmente sustituido con fenilo (en el cual, el fenilo está opcionalmente sustituido con sustituyentes independientemente seleccionados del grupo que consiste de halogeno, alquilo C1-4, alcoxi C1-4, amino, nitro y ciano).
ARP020100698A 2001-02-27 2002-02-27 Uso de compuestos carbamatos en la prevencion o el tratamiento de trastornos de movimiento AR033426A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27168301P 2001-02-27 2001-02-27
US10/081,501 US6589985B2 (en) 2001-02-27 2002-02-21 Carbamate compounds for use in preventing or treating movement disorders

Publications (1)

Publication Number Publication Date
AR033426A1 true AR033426A1 (es) 2003-12-17

Family

ID=26765643

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020100698A AR033426A1 (es) 2001-02-27 2002-02-27 Uso de compuestos carbamatos en la prevencion o el tratamiento de trastornos de movimiento

Country Status (28)

Country Link
US (1) US6589985B2 (es)
EP (1) EP1411917B1 (es)
JP (1) JP2004527492A (es)
KR (1) KR100858232B1 (es)
CN (1) CN1262272C (es)
AR (1) AR033426A1 (es)
AT (1) ATE369130T1 (es)
AU (1) AU2002247204B2 (es)
BR (1) BR0207831A (es)
CA (1) CA2439478C (es)
CY (1) CY1106924T1 (es)
CZ (1) CZ20032299A3 (es)
DE (1) DE60221670T2 (es)
DK (1) DK1411917T3 (es)
ES (1) ES2291454T3 (es)
HK (1) HK1067305A1 (es)
HU (1) HUP0303344A3 (es)
IL (2) IL157592A0 (es)
MX (1) MXPA03007719A (es)
MY (1) MY157373A (es)
NO (1) NO20033803L (es)
NZ (1) NZ551954A (es)
PL (1) PL364679A1 (es)
PT (1) PT1411917E (es)
RS (1) RS50676B (es)
RU (1) RU2294739C2 (es)
TW (1) TWI331524B (es)
WO (1) WO2002067926A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ523851A (en) * 2000-07-21 2004-09-24 Ortho Mcneil Pharm Inc A method for use of carbamate enantiomers in preventing or treating neuropathic pain and cluster and migraine headache-associated pain
CN1235579C (zh) * 2001-02-27 2006-01-11 奥索-麦克尼尔药品公司 用于预防或治疗神经变性疾病的氨基甲酸酯化合物
CA2454049A1 (en) 2001-07-16 2003-01-30 Ortho-Mcneil Pharmaceutical, Inc. Carbamate compounds for use in preventing or treating neuropathic pain
EP1890684B1 (en) 2005-06-08 2013-08-14 SK Biopharmaceuticals Co., Ltd. Treatment of sleep-wake disorders
PE20070325A1 (es) * 2005-06-29 2007-05-12 Alza Corp Formas de dosificacion oral que comprenden compuestos derivados de carbamato
EP1928451B1 (en) * 2005-07-26 2011-12-28 SK Biopharmaceuticals Co., LTD Methods for treating substance-related disorders
JP2010508354A (ja) * 2006-10-31 2010-03-18 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 広汎性発達障害の処置
KR101783633B1 (ko) 2009-11-06 2017-10-10 에스케이바이오팜 주식회사 섬유근육통 증후군의 치료 방법
US8895609B2 (en) 2009-11-06 2014-11-25 Sk Biopharmaceuticals Co., Ltd. Methods for treating attention-deficit/hyperactivity disorder
US8623913B2 (en) * 2010-06-30 2014-01-07 Sk Biopharmaceuticals Co., Ltd. Methods for treating restless legs syndrome
US9610274B2 (en) 2010-06-30 2017-04-04 Sk Biopharmaceuticals Co., Ltd. Methods for treating bipolar disorder
US8609849B1 (en) 2010-11-30 2013-12-17 Fox Chase Chemical Diversity Center, Inc. Hydroxylated sulfamides exhibiting neuroprotective action and their method of use
WO2014142477A1 (en) * 2013-03-12 2014-09-18 Bio-Pharm Solutions Co., Ltd. Phenyl carbamate compounds for use in preventing or treating pediatric epilesy and epilesy-related syndromes
EP2970111A4 (en) 2013-03-12 2017-01-18 Bio-Pharm Solutions Co., Ltd. Phenyl carbamate compound and a composition for preventing or treating a nerve gas-induced disease comprising the same
JP6807941B2 (ja) * 2016-02-29 2021-01-06 バイオ−ファーム ソリューションズ カンパニー リミテッド スルファメート誘導体化合物、その製造方法および用途
US10195151B2 (en) 2016-09-06 2019-02-05 Jazz Pharmaceuticals International Iii Limited Formulations of (R)-2-amino-3-phenylpropyl carbamate
MX2019006941A (es) * 2016-12-14 2019-09-06 Sk Biopharmaceuticals Co Ltd Uso de compuesto de carbamato para prevenir, aliviar o tratar temblores o el sindrome de temblor.
AU2018278332B2 (en) 2017-06-02 2022-05-19 Jazz Pharmaceuticals Ireland Limited Methods and compositions for treating excessive sleepiness
US10940133B1 (en) 2020-03-19 2021-03-09 Jazz Pharmaceuticals Ireland Limited Methods of providing solriamfetol therapy to subjects with impaired renal function
WO2022045824A1 (en) * 2020-08-31 2022-03-03 Bio-Pharm Solutions Co., Ltd. Phenyl alkyl carbamate compounds for use in preventing or treating neurodegenerative disease

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3313692A (en) 1958-04-21 1967-04-11 Armour Pharma Method of inducing calming and muscle relaxation with carbamates
US3265728A (en) * 1962-07-18 1966-08-09 Armour Pharma Substituted phenethyl carbamates
US5698588A (en) * 1996-01-16 1997-12-16 Yukong Limited Halogen substituted carbamate compounds from 2-phenyl-1,2-ethanediol

Also Published As

Publication number Publication date
DE60221670D1 (de) 2007-09-20
NZ551954A (en) 2008-07-31
DK1411917T3 (da) 2007-09-24
CA2439478A1 (en) 2002-09-06
IL157592A (en) 2009-12-24
NO20033803L (no) 2003-10-10
HK1067305A1 (en) 2005-04-08
HUP0303344A3 (en) 2012-07-30
CA2439478C (en) 2010-05-18
KR20030074847A (ko) 2003-09-19
EP1411917A1 (en) 2004-04-28
TWI331524B (en) 2010-10-11
IL157592A0 (en) 2004-03-28
BR0207831A (pt) 2004-06-22
AU2002247204B2 (en) 2006-08-24
CN1505508A (zh) 2004-06-16
DE60221670T2 (de) 2008-04-30
EP1411917B1 (en) 2007-08-08
NO20033803D0 (no) 2003-08-26
JP2004527492A (ja) 2004-09-09
ATE369130T1 (de) 2007-08-15
CN1262272C (zh) 2006-07-05
MXPA03007719A (es) 2004-11-12
PL364679A1 (en) 2004-12-13
WO2002067926A1 (en) 2002-09-06
RS50676B (sr) 2010-06-30
ES2291454T3 (es) 2008-03-01
KR100858232B1 (ko) 2008-09-12
RU2003128985A (ru) 2005-03-10
YU67703A (sh) 2006-08-17
US20020151585A1 (en) 2002-10-17
CZ20032299A3 (cs) 2004-08-18
HUP0303344A2 (hu) 2004-01-28
CY1106924T1 (el) 2012-09-26
RU2294739C2 (ru) 2007-03-10
MY157373A (en) 2016-06-15
US6589985B2 (en) 2003-07-08
PT1411917E (pt) 2007-09-17

Similar Documents

Publication Publication Date Title
AR033426A1 (es) Uso de compuestos carbamatos en la prevencion o el tratamiento de trastornos de movimiento
AR054524A1 (es) Metodos y formas de dosificacion para reducir los efectos secundarios de compuestos de carbamato
AR035756A1 (es) Uso de carbamatos en la preparacion de medicamentos para la prevencion o tratamiento de trastornos neurodegenerativos
ECSP088179A (es) Compuestos de carbamato para usarse en el tratamiento de desordenes neurodegenerativos
BRPI0515374A (pt) métodos de tratamento de epileptogenêse e epilepsia
AR033427A1 (es) Uso de compuestos carbamatos en el tratamiento del dolor
AR052885A1 (es) Metodos para el control del intervalo qt
AR054550A1 (es) Metodos para tratar la epileptogenesis
DK1408953T3 (da) Carbamatforbindelser til anvendelse til forebyggelse eller behandling af bipolær sygdom
MY133370A (en) Carbamate compounds for use in preventing or treating bipolar disorders
AR032876A1 (es) Compuestos de carbamato para utilizar en la prevencion o tratamiento de los trastornos psicoticos
DE60210960D1 (de) Carbamat-verbindungen zur prävention oder behandlung von angstzuständen
PT1305082E (pt) Compostos de carbamato para utilizacao na prevencao ou tratamento da dor neuropatica e dor associada a cefaleia de salvas e enxaqueca
AR032907A1 (es) Uso de compuestos carbamatos para la prevencion o tratamiento de trastornos de ansiedad
AR033428A1 (es) Compuestos carbamatos para su uso en la prevencion o tratamiento de trastornos bipolares
DK1408954T3 (da) Carbamatforbindelser til anvendelse ved forebyggelse eller behandling af neuropatisk smerte
AR034785A1 (es) Compuestos de carbamato para utilizarse en la prevencion o tratamiento de dolor neuropatico y dolor asociado con cefalea migranosa y cefalea acuminada
AR035757A1 (es) Uso de carbamatos para la fabricacion de medicamentos para prevenir o tratar un trastorno bipolar
MY136733A (en) Carbamate compounds for use in preventing or treating psychotic disorders
AR034786A1 (es) Compuestos de carbamato para utilizarse en la prevencion o tratamiento de dolor neuropatico y dolor asociado con cefalea migranosa y cefalea acuminada
AR033545A1 (es) Uso de compuestos de carbamato para la fabricacion de medicamentos
MY136347A (en) Carbamate compounds for use in preventing or treating neuropathic pain and cluster and migraine headache-associated pain

Legal Events

Date Code Title Description
FB Suspension of granting procedure